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gional differences ranging from testing 44% to more than 100% of the eligible pa-
tients, implying overuse of diagnostic tests in the latter case. Moreover, there was
a long waiting-time before results of EGFR-mutation tests were available (mean
11.9 days, SD 4.3 days). Considering treatment, on average about 45% of the eligible
patients were treated with EGFR-TKI in the first line. Regional variation was ob-
served ranging from 32% to 84%. Furthermore, extensive treatment variation was
observed, which was not according to current clinical guidelines. CONCLUSIONS:
The probability of testing patients for EGFR and treatments given varied consider-
ably. This did not correspond with current clinical guidelines. Less than 50% of the
eligible patients received EGFR-TKI in the first line. Reasons may be the long wait-
ing-time for test results, physicians experience and individual patient character-
istics. However, the large regional differences plead for optimal use of existing
diagnostic and treatment strategies to improve outcomes for this patient group.
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OBJECTIVES: To determine the extent of social inequality in uptake of prostate
cancer screening in Ireland and compare inequalities across groups for whom the
cost effectiveness of screening is thought to vary. METHODS: A series of decompo-
sition analyses of inequalities in uptake of prostate cancer screening were under-
taken using data collected as part of a large population based survey in the Republic
of Ireland (SLAN 2007). Separate analyses were conducted for individuals differen-
tiated by age on the basis of reported differences in the cost effectiveness of screen-
ing. A range of explanatory variables were used to explore the role of non-need
factors in inequalities including education and possession of private medical
insurance.RESULTS:Overall uptake of prostate screening in men aged 40 years and
over in the preceding 12 months was 23.81%. Uptake was highest among those in
the age group where the cost effectiveness of screening was deemed to be highest
(based on the findings of the European Randomised Study of Prostate Cancer (ER-
SPC) trial). The lowest socioeconomic inequality was also observed among this age
group. The decomposition of the concentration indices showed that possession of
private insurance was the largest determinant of inequality among those 55-69
(36%) and remained a significant determinant among those aged 40-54 (26%) and
aged 70 and over (17%). CONCLUSIONS: The decision to engage with screening is
one likely to be taken in conjunction with a healthcare professional and reflect an
assessment of the expected costs and benefits of screening to the individual.
Where evidence as to the merits of screening is ambiguous and financial incentives
to screen are evident patterns of uptake may emerge that does not represent an
appropriate use of resources and warrant greater scrutiny. KEY WORDS: Prostate
Cancer PSA Test Screening Incidence Diagnosis Concentration Indices Decompo-
sition Analysis
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OBJECTIVES: The European Parliament called for a greater focus on viral hepatitis
and hepatocellular carcinoma (HCC), yet there has been little action on this decla-
ration. We conducted a needs assessment for HCC control and tested needs con-
cordance in five European countries. METHODS: Clinical, policy and patient advo-
cacy stakeholders were purposively sampled from France, Germany, Italy, Spain,
and Turkey. Ten indicators were assessed subjectively: clinical education; early
risk assessment; HBV strategy; HCV strategy; life-style risk factors; national statis-
tics; funding for detection; funding for treatment; political awareness; and public
awareness. Results were compared to a benchmark using a Z-score and concor-
dance tested via the F-test. RESULTS: One hundred participants (response
rate37%) were drawn equally from the 5 countries. Respondents self-identified as
having influence at the local (33%), national (39%), or international (28%) level.
Greatest need is for improvement in life-style risk factors (Z-9.51), political
awareness (Z-7.97), and public awareness (Z-7.67), while the least need is for
improved HBV strategies (Z10.40). Overall, France performed best (Z4.26), and
Turkey worst (Z-2.54). Significant discordances in needs (P0.05) were found for
half of the factors (funding for treatment and detection, public awareness, HBV
strategy and national statistics), but concordance was accepted for the remaining
factors. CONCLUSIONS: We demonstrated a statistical method for conducting a
needs assessment for HCC control in Europe and found that the greatest needs are
for improving life-style risk factors (especially related to obesity and diabetes) and
political and public awareness. Despite being a cost-effective measure, HBV control
strategies are needed the least (mainly due to prior adoption). With both concor-
dant and discordant needs, there are roles for both national and European-wide
efforts in HCC control. For example, the European parliament should lead efforts in
driving political awareness and lifestyle risk factors, while member countries
should focus on public awareness.
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OBJECTIVES:Overall 2506 patients gained access (from a total of 2880 applications)
for oncology treatment from the Cancer Drugs Fund within the first 6 months of its
launch. However, there are significant variations in the number of applications that
different Strategic Health Authorities (SHAs) are able to process and approve. This
study aims to assess the underlying reasons for the observed inter regional vari-
ability in the application rates, processing and outcomes within the Cancer Drugs
Fund from October 2010 to March 2011. METHODS: The results on the application
rates from an audit undertaken by Rarer Cancers Foundation using the Freedom of
Information Act were analysed, especially, the change in application rate over time
and the outcomes of these requests. The analysis led to the development of a
framework to understand the key factors influencing the application rates and its
outcomes, which was then validated through a telephone survey of key SHAs in
2011. RESULTS: Along with significant variations in the application rate, there
appears to be a north-south divide, with SHAs in the south of England approving a
lower proportion of applications. Some of the underlying reasons were identified to
be linked with administration costs, levels of routine access to cancer treatments
(which itself vary according to the area of the country) and ‘timely’ decision-mak-
ing ability. CONCLUSIONS: Some of the notable practices identified towards expe-
diting the processing of applications can form recommendations for robust process
development in future for the upcoming clinical commissioning consortia to guide
their commissioning activities. Future steps can include benchmarking of their
application approval rates by clinical commissioning consortia (and SHAs until
2013) against that in other region and take action to identify the outliers and ad-
dress the causes of this.
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OBJECTIVES: Substantial differences in cancer-related mortality rates among the
16 provinces of Poland exist. Over the last 10 years the differences between the
highest and the lowest observed standardized mortality rates varied at 33.9% to
54.2% in female population and at 24.1% to 40.9% in male population. The differ-
ences in mortality rates cannot be explained only by differences in cancer inci-
dence rates among the provinces since weak correlation between both this values
exist (Pearson’s correlation r0.33 and r0.36 in male and female population, re-
spectively). There are also substantial differences in availability of oncology care
among the provinces since to some extent each of 16 regional departments of the
National Health Fund (NHF) pursues its own health policy. The aim of this study
was to estimate whether the differences in availability of oncology care are respon-
sible for differences in cancer-related mortality among the provinces of Poland.
METHODS: We used NHF data on contracts for oncology hospital and ambulatory
care in 2008 and the National Cancer Registry (NCR) data on age-standardized
mortality rates due to cancer in 2008. Data on hospital and ambulatory care and
incidence data for each province were used to estimate availability of oncology care
per cancer patient. Incidence data were used due to lack of cancer precise preva-
lence data. RESULTS: We have found no strict correlation between mortality rates
and availability of hospital care with Pearson’s correlation r-0.01 and r-0.05 in
male and female population, respectively. Surprisingly weak positive correlations
between mortality rates and availability of ambulatory care were found with Pear-
son’s correlation r0.36 and r0.45 in male and female population, respectively.
CONCLUSIONS: Further research, extended beyond simple relation between clin-
ical outcomes and health care service financing is needed to explore inter-prov-
inces variability. International Research Project on Financing Quality in Healthcare
InterQuality, is aimed to address those discrepancies in health care.
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OBJECTIVES: Human Papilloma Virus (HPV) vaccination programs among women
have been successfully implemented in Europe. Burden of HPV-related cancers is
rising in Europe in men and represents around 30% of the overall HPV-related
burden in both genders. Vaccinating girls have an indirect protective impact on
males but doesn’t avoid the whole HPV burden. Study objective was to have a first
estimate of the incremental benefits of vaccinating males and females compared to
females only, in Europe. METHODS: An Excel-based model was developed to esti-
mate impact of vaccinating boys and girls with a quadrivalent-HPV6/11/16/18 vac-
cine on HPV-related diseases: anal, penile, head and neck, vaginal, vulvar and
cervical cancers and genital warts. Epidemiological reductions due to vaccination
were derived from a US dynamic transmission model. Epidemiological data and
demographic inputs came from published literature. The analysis estimates the
incremental clinical benefits of adding a cohort of 12-years old boys to a 12-years
old girls vaccination program. Seventy percent vaccine coverage rates were as-
sumed for both strategies. RESULTS: A validation of this model was achieved by
being able to replicate US dynamic model results (number of cases avoided). In
Europe, female-only vaccination would result in a 61% reduction in males HPV-
related cancers (at steady state; 100 years). Adding a cohort of boys would increase
this result to 86% and would avoid significant additional HPV-related diseases
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(3,584 cancers, 88,514 genital warts annually). Head and neck cancers represent the
majority of additional cancers avoided. Boys’ vaccination would allow a further
reduction in females’ cases thanks to indirect protection. CONCLUSIONS: Model
simulations were robust as they replicated US published results. This first analysis
showed that vaccinating boys in addition of girls had the potential to prevent a
significant number of additional cases. Country specific analysis will be useful to
take into account different vaccination programs in place.
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OBJECTIVES: Since the inception of economic evaluation for new drug reimburse-
ment decisions in 2007, there have been modifications on this policy. While this
reflects in itself the imperfect systematic adoption of economic evaluation from
the beginning, it has been pointed out that the current scheme relying on the proof
of cost-effectiveness value remains silent on crucial issues related to the opportu-
nity cost from a system perspective and fair access to treatment. This study was
aimed to discover how much social judgment was prudently considered in the
reimbursement decision process especially for oncology medications in Korea.
METHODS: Public review documents drawn by the Health Insurance Review and
Assessment Agency on oncology medications were collected and analyzed to ex-
amine the concrete shape of public accountability. For external comparison, cor-
responding public documents presented by the Pharmaceutical Benefits Advisory
Committee of Australia and the National Institute for Health and Clinical Excel-
lence of UK were also pulled together and analyzed. Finally, not only clinical and
economic evidence factors but also non-evidentiary factors such as equity and
historical precedent revealed through the analytical works were discussed in depth
by interviewing oncologists as representative stakeholders. RESULTS: Among 12
cancer drugs, five received positive decision from January, 2007 to June, 2009. Clin-
ical study data and price of drugs seemed the mostly considered standard for
reimbursement decision. The social judgment in this study implied the reconsid-
eration on the following issues: 1) the composition of Drug Reimbursement Evalu-
ation Committee; 2) the rationale of using cost-effectiveness data; 3) equity for rare
cancer patients; 4) words clarity in public documents; 5) transparent decision pro-
cess; and 6) budget impact results. CONCLUSIONS: Besides focusing on the im-
provement of technical evidence in HTA, a greater effort should be made for the
reasonable decision process reflecting societal desirability, public agreement and
judgments on social value.
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OBJECTIVES: Anti-cancer drug formulary has been managed by the government in
Korea and needs to be updated for better clinical outcomes. This study was to
evaluate current anti-cancer drug formulary focusing on pancreatic neuroendo-
crine tumors (PNET) and then propose the new formulary reimbursement criteria.
METHODS: The drugs on the formulary and the drugs approved for the treatment
of PNET were reviewed whether their use and reimbursement was appropriate in
the view of the evidence-based approach. The oncology textbooks and clinical
practice guidelines were reviewed also. PubMed search for the primary drug liter-
ature was performed with MeSH terms (pneuroendocrine tumors, pancreatic neo-
plasms, islet cell adenoma, islet cell carcinoma, and gastro-enteropancreatic neu-
roendocrine tumor) and the limits (clinical trial, and publication date to April 30,
2011). Published clinical research data were critically rated with the pre-deter-
mined literature evidence strength levels and the new formulary was proposed.
RESULTS:Only one anti-cancer drug (sunitinib) was approved in Korea, although it
was not proposed as a first-line in the clinical guidelines (NCCN, ESMO) and a
textbook (Abeloff’s). Although it was not on the national formulary list, a recently
published randomized controlled phase 3 trial would support its use in a certain
type of PNET as a primary chemotherapy. The already listed drugs revealed to be
evidence-supported but with relatively weak strength levels. National formulary
appeared to be reformulated with refined criteria (drug dosage and cancer types,
etc). CONCLUSIONS: Sunitinib should be listed on the national anti-cancer drug
formulary with a restricted reimbursement criteria of “treatment of unresectable
or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease
progression in adults” as described in the approved indication and pivotal clinical
research data. Next step of the research of this area would be to examine clinical
outcomes with this formulary change.
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OBJECTIVES: Cervical cancer is the third most common gynecologic cancer in the
United States. Currently there are two proven approaches to cervical cancer pre-
vention: conventional cytology screening and human papillomavirus (HPV) vacci-
nation. Prevention guidelines recommend screening every one to three years after
onset of sexual activity. In addition, many states have passed legislation to require
mandatory HPV vaccination for school children. The study aims to compare the
cost-effectiveness of HPV vaccination combined with conventional cytology
screening versus HPV vaccination alone on cervical cancer prevention in the US.
METHODS:A decision tree was used to estimate the lifetime costs (in 2004 US$) and
outcomes for U.S. women receiving HPV vaccination or mandatory HPV vaccina-
tion combined with conventional cytology screening from the societal perspective.
The costs and epidemiological data were derived from published literature and
health institution websites. Outcomes included life expectancy and quality-ad-
justed life years (QALYs) gained. RESULTS: The incremental cost-effectiveness ra-
tio (ICER) for HPV vaccination combined with the triennial screening compared to
vaccination alone was $251,965 per QALY gained. The result was most sensitive to
the total costs of conventional cytology screening. When the total costs of conven-
tional cytology screening varied from $30 to $319, the ICER increased from $98,669
to $1,006,860 per QALY gained. When increasing the frequency of screening to
biennial and annual, the ICER of HPV vaccination combined with screening com-
pared to vaccination alone changed to $335,533 and $592,991 per QALY gained
respectively. CONCLUSIONS: These results indicate that conventional cytology
screening provides little benefit beyond that provided by HPV vaccination. They
suggest that routine cytology screening should no longer be recommended for
women who have been successfully vaccinated.
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OBJECTIVES: Expensive hospital anti-cancer drugs are funded separately from the
activity-based payments. Reimbursement tariffs are set for a list of drugs including
a large proportion of anti-cancer drugs. This funding aims to ensure equity of
access to innovation throughout the French territory. Our objective was to describe
the use of the expensive anti-cancer drugs in French hospitals and to investigate
whether differences existed between the public and private sector and between
regions. METHODS: We used a sample of 448 hospitals authorized to deliver che-
motherapies. The Groupement pour l’Elaboration et la Réalisation de Statistique
provided the sales per drug and per hospital in the year 2008. Hospital character-
istics were extracted from two national surveys (Programme de Médicalisation des
Systèmes d’Information and Statistique Annuelle des Etablissements de santé). We
conducted a multilevel analysis. The dependent variable was the mean expendi-
ture per chemotherapy session and per hospital. Independent variables were hos-
pital capacity, the volume of activity, case-mix for chemotherapies and the per-
centage use of biological drugs. At the regional level, we used the mean annual
wage, inequality of wage distribution, the density of general practitioners, cancer
incidence and mortality. RESULTS: The sales of anti-cancer drugs were estimated
at 1713 million Euros. The mean expenditure per chemotherapy session was € 923
[CI: 890-954]. It was significantly higher in the private sector: €970 versus €891,
p0.02. At the hospital level, a case-mix of specialized chemotherapies for breast
cancers and the percentage use of biological drugs were associated with a higher
expenditure of anti-cancer drugs per session. There were no differences between
the mean expenditures per region. CONCLUSIONS: The absence of disparities in
the use of anti-cancer drugs between regions suggests that the reimbursement
tariffs have promoted equal access to innovative treatments throughout the terri-
tory.
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OBJECTIVES: To estimate direct annual healthcare utilization and costs of for pa-
tients with head and neck cancer. METHODS: The 2008 Medical Expenditure Panel
Survey (MEPS) database, a nationally representative annual survey of the civilian
non-institutionalized population of the U.S was used. Patients’ data were extracted
if they had a Clinical Classification Code (CCC) for head and neck cancer (code 11)
and International Classification of Disease 9 (ICD-9) code of 140.xx-149.xx or
160.xx-161.xx. The SURVEYREG procedure in SAS for weighted populations was
used. RESULTS: Only 17 patients (representing 223,263 persons) met inclusion cri-
teria, therefore weighting may not be robust. Direct unweighted medical costs
attributable to cancer were estimated at $6,171  11,288 (mean  standard devia-
tion) per patient. Approximately half ($ 2860 6399) of this estimate was generated
by outpatient costs. Physician office visits ($1,609 4,291) and inpatient hospital
visits ($1225 5054) contributed to most of the remaining costs. If MEPS weightings
were used, the total costs were estimated at $ 8629 - again with about half gener-
ated by outpatient costs, and the majority of remaining costs split between office
visits and hospitalizations. Since MEPS only provides 3 digits of the 5-digit ICD-9,
some patients may have been missed as we did not include some ICD9s listed by
CCC 11; such as 195.xx “Malignant neoplasm of other and ill-defined sites” nor
230.xx “Carcinoma in situ of digestive organs” which included some cancers re-
lated to the head and neck (e.g. 230.0 - Carcinoma in situ of lip oral cavity and
pharynx) as well as others not related to these areas (e.g. 230.3 - Carcinoma in situ
of colon). CONCLUSIONS: The sample size was small in this database. Future stud-
ies should be conducted using databases with more patients and/or a more precise
level of diagnosis coding.
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